PAVmed Inc
PAVmed Inc (PAVMZ) Stock Overview
Explore PAVmed Inc’s financial performance, market position, analyst ratings, and future outlook.
PAVMZ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PAVmed Inc (PAVMZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.07.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.12 and a market capitalization of 11.9K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Dr. Lishan Aklog M.D.
39
360 Madison Avenue, New York City, DE
2018